Driver, 18, killed in Pubnico crash
An 18-year-old Lower West Pubnico, N.S., man died in a single-vehicle crash in Pubnico, N.S., early Friday morning.
In a news release, Nova Scotia RCMP said the crash was reported on Highway 335 near Cross Road shortly after midnight.
Police said a pickup truck, a GMC Sierra, left the roadway and landed in a ditch.
The 18-year-old man who was driving was pronounced dead at the scene.
A passenger, a 21-year-old man from Lower West Pubnico, was taken to hospital with serious injuries.
The highway was closed for several hours following the crash.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
16 minutes ago
- CTV News
Toronto police seeing increased reports of pickpockets targeting cellphones at public festivals
A Toronto Police emblem is shown in Toronto on Aug. 5, 2022. THE CANADIAN PRESS/Cole Burston Toronto police say they're seeing a spike in the number of pickpockets targeting cellphones at public festivals in the city. In a news release issued Thursday, police said in May and June 2025 they received 'increased reports' of cellphone thefts at locations where crowds gathered for public festivals throughout 14 Division in the city's west end. Police didn't say which festivals the thefts occurred at, but popular events like the Taste of Little Italy and Do West Fest, among others, took place in that area of the city earlier this month. 'Suspects are stealing cell phones from bags, backpacks, pockets, purses, and those left momentarily unattended. In some cases, the suspects removed cell phones from zipped-closed purses and bag pockets,' police said. Police are reminding anyone who's planning to attend a festival in the city this summer, of which there are several, to be 'mindful' of their belongings in crowded public spaces. They advise to: Stay alert when you're out at festivals or any large events. Ensure your phone and other valuables are never out of your sight. Make sure that your phone and other valuables are always secured close to your body. Don't put cell phones in your back pocket where a thief can easily grab it. Anyone who's been a victim of a cellphone theft is asked to contact police to report it.
Globe and Mail
27 minutes ago
- Globe and Mail
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program
Canada's Largest Medical Cannabis Company Offers the Country's Most Inclusive Medical Cannabis Pricing Program NASDAQ| TSX: ACB EDMONTON, AB, June 26, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 CAD for Aurora patients through
National Post
44 minutes ago
- National Post
KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
Article content -Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada- Article content -Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic areas with capabilities to launch sebetralstat in Canadian market- Article content Article content CAMBRIDGE, Mass. & SALISBURY, England — KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE). Article content 'We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE,' said Ben Palleiko, CEO of KalVista. 'This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care.' Article content Financial terms of the agreement are not being disclosed. Article content About Sebetralstat Article content Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older and are investigating its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. Article content About Hereditary Angioedema Article content Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. Article content About KalVista Pharmaceuticals, Inc. Article content KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. Article content About Pendopharm Article content Pendopharm, a division of Pharmascience Inc., is a Canadian specialty pharmaceutical company that partners with various companies to bring treatments in areas such as rare diseases, gastroenterology, sports medicine, neurology, and cardiology to the Canadian market. For more information about Pendopharm, please visit Article content About Pharmascience Inc. Article content Headquartered in Montreal, Pharmascience Inc. is one of Canada's largest pharmaceutical manufacturers, supplying high-quality medicines to over 50 countries. Its global reach and agile development model ensure timely responses to patient needs worldwide. Article content Forward-Looking Statements Article content This press release contains 'forward-looking' statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will,' and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timings or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Article content Article content Article content Article content Article content Contacts Article content
